

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

BIOLOGICS LICENSE APPLICATION FOR CU-20101 (BOTULINUM TOXIN TYPE A FOR INJECTION) ACCEPTED BY THE NMPA

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Biologics License Application (BLA) for the Group’s CU-20101 (botulinum toxin type A for injection) has been accepted by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China. The indication is for improving moderate to severe glabellar lines.

CU-20101 will not use animal-derived materials and human serum albumin in its manufacturing process, thereby eliminating the risk of transmissible spongiform encephalopathies (TSE) infection and related allergic reactions, and is expected to have a favorable safety advantage. CU-20101 will further enrich the Group’s skin product portfolio and facilitate synergies with the Group’s existing products. Facing the broad demands of the skin treatment market, a diversified product portfolio is expected to enable the Group to further increase its market share.

Warning: There is no assurance that CU-20101 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Cutia Therapeutics

Zhang Lele

Chief Executive Officer and Executive Director

Hong Kong, 3 September 2026

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.